127 related articles for article (PubMed ID: 37277928)
1. Cyclical 10-day dosing of melphalan for canine multiple myeloma.
Teddy L; Sylvester SR; O'Connor KS; Hume KR
Vet Comp Oncol; 2023 Sep; 21(3):533-540. PubMed ID: 37277928
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs.
Fernández R; Chon E
J Vet Intern Med; 2018 May; 32(3):1060-1069. PubMed ID: 29566439
[TBL] [Abstract][Full Text] [Related]
3. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic atypical myeloma with extensive cutaneous involvement in a dog.
Fukumoto S; Hanazono K; Kawasaki N; Hori Y; Higuchi S; Sasaki T; Temma K; Uchide T
J Vet Med Sci; 2012 Jan; 74(1):111-5. PubMed ID: 21873808
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Evaluation of Melphalan, Vincristine, and Cytarabine Chemotherapy for the Treatment of Relapsed Canine Lymphoma.
Duckett ME; Curran KM; Bracha S; Leeper HJ
J Am Anim Hosp Assoc; 2024 Jan; 60(1):7-14. PubMed ID: 38175982
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a multi-agent chemotherapy protocol combining dexamethasone, melphalan, actinomycin D, and cytarabine for the treatment of resistant canine non-Hodgkin high-grade lymphomas: a single centre's experience.
Smallwood K; Tanis JB; Grant IA; Blackwood L; Killick DR; Amores-Fuster I; Elliott J; Mas A; Harper A; Marrington M; Finotello R
Vet Comp Oncol; 2019 Jun; 17(2):165-173. PubMed ID: 30666777
[TBL] [Abstract][Full Text] [Related]
7. Canine Cutaneous Plasmacytosis: 21 Cases (2005-2015).
Boostrom BO; Moore AS; DeRegis CJ; Robat C; Freeman K; Thamm DH
J Vet Intern Med; 2017 Jul; 31(4):1074-1080. PubMed ID: 28514049
[TBL] [Abstract][Full Text] [Related]
8. Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease.
Pulsoni A; Villivà N; Cavalieri E; Falcucci P; La Verde G; Matera R; Petrucci MT; Tosti ME; Mandelli F
Drugs Aging; 2002; 19(12):947-53. PubMed ID: 12495369
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
10. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Palumbo A; Bertola A; Musto P; Caravita T; Callea V; Nunzi M; Grasso M; Falco P; Cangialosi C; Boccadoro M
Cancer; 2005 Oct; 104(7):1428-33. PubMed ID: 16116606
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma with associated polyneuropathy in a German shepherd dog.
Villiers E; Dobson J
J Small Anim Pract; 1998 May; 39(5):249-51. PubMed ID: 9631362
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.
San-Miguel JF; Echeveste Gutierrez MA; Špicka I; Mateos MV; Song K; Craig MD; Bladé J; Hájek R; Chen C; Di Bacco A; Estevam J; Gupta N; Byrne C; Lu V; van de Velde H; Lonial S
Haematologica; 2018 Sep; 103(9):1518-1526. PubMed ID: 29954932
[TBL] [Abstract][Full Text] [Related]
13. Retrospective evaluation of the use of the International Myeloma Working Group response criteria in dogs with secretory multiple myeloma.
Moore AR; Harris A; Jeffries C; Avery PR; Vickery K
J Vet Intern Med; 2021 Jan; 35(1):442-450. PubMed ID: 33215766
[TBL] [Abstract][Full Text] [Related]
14. Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs.
Back AR; Schleis SE; Smrkovski OA; Lee J; Smith AN; Phillips JC
Vet Comp Oncol; 2015 Dec; 13(4):398-408. PubMed ID: 23910023
[TBL] [Abstract][Full Text] [Related]
15. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
[TBL] [Abstract][Full Text] [Related]
16. Biclonal gammopathy associated with immunoglobulin A in a dog with multiple myeloma.
Ramaiah SK; Seguin MA; Carwile HF; Raskin RE
Vet Clin Pathol; 2002; 31(2):83-9. PubMed ID: 12040490
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for multiple myeloma in the dog.
Matus RE; Leifer CE; MacEwen EG; Hurvitz AI
J Am Vet Med Assoc; 1986 Jun; 188(11):1288-92. PubMed ID: 3721983
[TBL] [Abstract][Full Text] [Related]
18. Oral melphalan for the treatment of relapsed canine lymphoma.
Mastromauro ML; Suter SE; Hauck ML; Hess PR
Vet Comp Oncol; 2018 Mar; 16(1):E123-E129. PubMed ID: 28941072
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.
Parsons-Doherty M; Poirier VJ; Monteith G
Can Vet J; 2014 Feb; 55(2):175-80. PubMed ID: 24489398
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma.
Alvarez FJ; Kisseberth WC; Gallant SL; Couto CG
J Vet Intern Med; 2006; 20(5):1178-83. PubMed ID: 17063713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
